AKR1B1

Aldo-keto reductase family 1 member B1 · P15121 · AKR1B1 on Sugi Atlas →

197,818 patent compounds predicted against AKR1B1, 142,417 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Zopolrestat (SCHEMBL49012)	1.00	20/20
Imirestat (SCHEMBL49034)	1.00	17/20
Ponalrestat (SCHEMBL49154)	1.00	17/20
SCHEMBL5835	0.52	11/20
Fidarestat (SCHEMBL48827)	1.00	10/20
(R,S)-Fidarestat (SCHEMBL48828)	1.00	10/20
Zenarestat (SCHEMBL48959)	1.00	8/20
Benzyl Cinnamate (SCHEMBL43212)	0.84	7/20
Benzyl Cinnamate (SCHEMBL43213)	0.84	7/20
Chlorogenic Acid (SCHEMBL19466)	1.00	6/20
Umbelliferone (SCHEMBL22018)	1.00	6/20
Phenethyl Cinnamate (SCHEMBL43631)	1.00	6/20
Phenethyl Cinnamate (SCHEMBL43632)	1.00	6/20
Reynoutrin (SCHEMBL38138)	0.71	6/20
SCHEMBL43817	0.59	6/20
SCHEMBL47328	0.51	6/20
Gossypol (SCHEMBL3939)	1.00	5/20
Isoquercetin (SCHEMBL23249)	1.00	5/20
Isoquercetin (SCHEMBL24609)	1.00	5/20
Tiopinac (SCHEMBL38905)	1.00	5/20

Clinical trials — most relevant to AKR1B1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
The Role of 5-alpha Reductase in Mediating Testosterone Actions	PHASE4	COMPLETED
The Role of Mineralocorticoid Receptors in Vascular Function	PHASE2/PHASE3	COMPLETED
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
Toxicity and Efficacy Evaluation of Topical Minoxidil in Acne Vulgaris	PHASE1/PHASE2	UNKNOWN
AMG 386 and Abiraterone for Advanced Prostate Cancer	PHASE2	COMPLETED
PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia	PHASE1/PHASE2	UNKNOWN
Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies	PHASE1	COMPLETED
Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole	nan	WITHDRAWN
Tissue Predictors of Abiraterone Benefit	nan	COMPLETED
Adrenoleukodystrophy National Registry Study	nan	RECRUITING
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
ALDH2 Genetic Testing in East Asian Community	nan	NOT_YET_RECRUITING
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy	nan	RECRUITING
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases	nan	COMPLETED
Influence of WNT4 VEZT FSHB and SIRT1 SNPs in Endometriosis: a Case Control Study of the Sardinian Population	nan	UNKNOWN
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
Pharmacogenetic Determinants Of Treatment Response In Children	nan	RECRUITING
Biomarkers in the Etiology of Idiopathic Intracranial Hypertension	nan	UNKNOWN
Individualized Antiretroviral Therapy	nan	COMPLETED
Pharmacogenetics of Alcohol: Treatment Implications	nan	COMPLETED
Gene Polymorphisms Influencing Steroid Synthesis and Action	nan	WITHDRAWN
Tamoxifen Pharmacogenetics in Asian Breast Cancer Women	nan	UNKNOWN
Androgens and NAFLD Longitudinal Cohort Study	nan	RECRUITING
Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China	nan	COMPLETED
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia	nan	RECRUITING
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC	nan	COMPLETED
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a AKR1B1 binder may also engage these)

Protein	Name	Similarity
P80276	—	1.000	P80276 →
P16116	—	1.000	P16116 →
Q5RJP0	—	1.000	Q5RJP0 →
P45377	—	0.999	P45377 →
AKR1B10	Aldo-keto reductase family 1 member B10	0.997	landscape →
P45376	—	0.996	P45376 →
AKR1D1	Aldo-keto reductase family 1 member D1	0.995	landscape →
P21300	—	0.995	P21300 →
P82125	—	0.995	P82125 →
P15122	—	0.995	P15122 →
Q9TV64	—	0.994	Q9TV64 →
Q28FD1	—	0.993	Q28FD1 →
Q6GMC7	—	0.993	Q6GMC7 →
O08782	—	0.993	O08782 →
P07943	—	0.993	P07943 →
P17264	—	0.991	P17264 →
Q8VCX1	—	0.989	Q8VCX1 →
C9JRZ8	—	0.986	C9JRZ8 →
AKR1A1	Aldo-keto reductase family 1 member A1	0.985	landscape →
Q8VC28	—	0.984	Q8VC28 →
P31210	—	0.984	P31210 →
Q9DCT1	—	0.982	Q9DCT1 →
P02532	—	0.981	P02532 →
M9PF61	—	0.980	M9PF61 →
Q5U1Y4	—	0.979	Q5U1Y4 →
Q5R5D5	—	0.978	Q5R5D5 →
Q3ZCJ2	—	0.977	Q3ZCJ2 →
O70473	—	0.976	O70473 →
Q0PGJ6	—	0.976	Q0PGJ6 →
Q5ZK84	—	0.976	Q5ZK84 →